United States

Threshold Pharmaceuticals Inc (THLD.O)

THLD.O on Consolidated Issue listed on NASDAQ Capital Market

26 May 2017
Change (% chg)

$0.01 (+2.02%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide
Thursday, 27 Aug 2015 07:00am EDT 

Threshold Pharmaceuticals Inc:Announces that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or 'tarloxotinib' (TH-4000), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).  Full Article

More From Around the Web

BRIEF-Threshold Pharmaceuticals files for non-timely 10-Q

* Threshold Pharmaceuticals says due to connectivity issues with Edgar server, co was unable to file form 10-Q for period ended March 31, 2017 Source text for Eikon: (http://bit.ly/2qtGHCc) Further company coverage: